LeanTaas, which counts Sedgwick Claims Management Services as an investor, closed a series C round led by Insight Venture Partners that will fund the growth of its platform.

The funding from crowdfunding platform SyndicateRoom is part of a wider series B round for Manchester gel therapy developer Gelmetix and adds to approximately $1.3m raised in 2014 and 2015.

Strategic partner Eli Lilly invested $15m while Pfizer, Ping An Ventures and Taiho Ventures also contributed to the immunotherapy developer's series B round.

Pfizer Ventures and 6 Dimensions Capital joined Merck & Co, Sanofi, Eli Lilly and Amgen in Kymera's series B round, taking the protein degradation drug developer's total funding to more than $95m.

Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.

The Medtronic and BioMed Realty-backed medical device developer bumped its overall funding to $113m with a round led by Solas BioVentures.

The sleep disorder treatment developer has raised an additional $17.1m in a round led by medical device maker Cochlear.

Boehringer Ingelheim and Helsinn helped University of Geneva vaccine spinout Amal reach the second close of a series B round that now totals $32.7m.

Existing investors SoftBank Vision Fund and Dexxon both returned for a $200m round that will help drug developer Roivant Sciences expand its range of subsidiaries.

Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.